You are here

  • Home
  • Archive
  • Volume 33, Issue 8
  • No founder effect in three novel Alzheimer's disease families with APP 717 Val-->Ile mutation. Clerget-darpoux. French Alzheimer's Disease Study Group.

Article Text

Article menu
Download PDFPDF
Research Article
No founder effect in three novel Alzheimer's disease families with APP 717 Val-->Ile mutation. Clerget-darpoux. French Alzheimer's Disease Study Group.
  1. D Campion,
  2. A Brice,
  3. D Hannequin,
  4. F Charbonnier,
  5. B Dubois,
  6. C Martin,
  7. A Michon,
  8. C Penet,
  9. M Bellis,
  10. A Calenda,
  11. M Martinez,
  12. Y Agid,
  13. F Clerget-Darpoux,
  14. T Frebourg
  1. Laboratoire de Génétique Moléculaire, CHU de Rouen.

    Abstract

    We sequenced exons 16 and 17 of the APP (amyloid precursor protein) gene in 18 unrelated French Alzheimer's disease (AD) patients. These patients had an onset before the age of 60 and belonged to families with autosomal dominant transmission of the disease. We detected the APP 717 Val-->Ile mutation in three out of 18 (16.6%) families. In these three families, all affected subjects had the APOE 3/3 genotype, but their ages of onset ranged from 38 to 60 years, indicating that factors other than the APOE genotype influence age of onset. Analysis of two polymorphic loci adjacent to the APP gene showed that at least two independent mutational events had occurred within these pedigrees, in spite of their origin in the same region of France.

    https://doi.org/10.1136/jmg.33.8.661

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.